Drug Profile
Domatinostat - 4SC
Alternative Names: 4SC-202Latest Information Update: 21 Mar 2023
Price :
$50
*
At a glance
- Originator Nycomed
- Developer 4SC; Netherlands Cancer Institute
- Class Antineoplastics; Benzamides; Pyrazoles; Pyrroles; Small molecules; Sulfones
- Mechanism of Action BRD4 protein modulators; HDAC1 protein inhibitors; HDAC2 protein inhibitors; HDAC3 protein inhibitors; Lysine specific demethylase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Bladder cancer; Cancer; Colorectal cancer; Gastrointestinal cancer; Haematological malignancies; Malignant melanoma; Merkel cell carcinoma; Oesophageal cancer; Pancreatic cancer; Small cell lung cancer; Triple negative breast cancer
Most Recent Events
- 31 Jul 2022 4SC and Vuja De Sciences enter into a material transfer and option agreement for domatinostat
- 22 Feb 2022 Discontinued - Phase-I for Bladder cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Neoadjuvant therapy) in Netherlands (IV)
- 22 Feb 2022 Discontinued - Phase-I for Haematological malignancies (Late-stage disease) in Germany (PO)